Showing results (281-290 of 403) with videos related to
Sort By:
Pageof 41
Managed Care Interface|April 15, 2008
The direct and indirect cost burden of atopic dermatitis: an employer-payer perspectiveJoseph F Fowler, Mei Sheng Duh, Ludmila Rovba, et al.Managed Care Interface|August 9, 2006
The economic burden of intracerebral hemorrhage: evidence from managed careMason W Russell, Luke Boulanger, Ashish V Joshi, et al.Managed Care Interface|August 9, 2006
Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysisJason F Simpson, Christopher B Yelverton, Rajesh Balkrishnan, et al.Managed Care Interface|August 11, 2006
Prevalence and economic consequences of medication adherence in diabetes: a systematic literature reviewWon Chan Lee, Sanjeev Balu, David Cobden, et al.Managed Care Interface|February 22, 2007
The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspectivePeggy S McKinnon, Chureen T Carter, Prafulla G Girase, et al.Managed Care Interface|June 9, 2005
Assessing potential risks and evaluating expected benefitsFadia T Shaya, Anna GuManaged Care Interface|April 27, 2007
Is managed care closing substance abuse treatment units?Rebecca Wells, Christy Harris Lemak, Jeffrey A Alexander, et al.Managed Care Interface|November 23, 2006
Managed care and clinical autonomy in the workers' compensation marketTricia JohnsonManaged Care Interface|May 13, 2006
A method classifying biologics for formulary decision makingMichael S Broder, Debi ReissmanPageof 41